Daiwa: Assigns "Buy" Rating to WUXI BIO (02269), Expects BIODLINK-B (01875) to Maintain Listing Status

Stock News14:48

Daiwa released a research report stating that WUXI BIO (02269) and WuXi XDC (02268) announced they will make a general offer to acquire at least 60% of the shares of BIODLINK-B (01875) for a maximum consideration of approximately 2.8 billion yuan, with expectations that BIODLINK-B will maintain its listing status post-completion. WuXi XDC anticipates that this acquisition will aid in business expansion, secure additional operational production capacity in China, further enrich its project portfolio, broaden its client base, and consolidate its leading market position in the ADC contract development and manufacturing organization (CDMO) sector. Daiwa currently assigns an investment rating of "Buy" to WUXI BIO.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment